Phase 1–2 study of vorinostat (SAHA), cladribine and rituximab (SCR) in relapsed B-cell non-Hodgkin lymphoma and previously untreated mantle cell lymphoma

Stephen Spurgeon, Kamal Sharma, David F. Claxton, Christopher Ehmann, Jeffrey Pu, Sara Shimko, August Stewart, Nan Subbiah, Gundula Palmbach, Francis LeBlanc, Emile Latour, Yiyi Chen, Motomi (Tomi) Mori, Zainul Hasanali, Elliot M. Epner

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Altered DNA methylation and histone acetylation in lymphoma provided the rationale for using vorinostat (SAHA), cladribine and rituximab (SCR) in non-Hodgkin lymphomas (NHL) in this phase 1–2 study (NCT00764517). Treatment included cladribine 5 mg/m2 intravenously (IV) (days 1–5), rituximab 375 mg/m2 IV (weekly 4× for cycle 1 and 1×/month) and vorinostat orally once daily (days 1–14) every 28 days for up to six cycles. Phase 1 included relapsed patients (n = 10) in a standard 3 + 3 dose escalation design (vorinostat: 200, 300 and 400 mg). No dose-limiting toxicities were seen. The phase 2 dose for vorinostat was 400 mg po (days 1–14). The majority of phase 2 patients had mantle cell lymphoma (MCL) (n = 57; 39 previously untreated, 10 relapsed). The primary objective was objective response rate [complete response (CR) + partial response] which was 39% (7/18) in relapsed patients and 97% (38/39) with 80% (31/39) attaining a CR in previously untreated MCL. At a median follow-up of 42 months, median progression-free survival (PFS) and overall survival (OS) for relapsed NHL were 19·5 [95% confidence interval (CI): 2·0–33·0] and 25·0 (95% CI: 12·0–45·0) months respectively. Median PFS for previously untreated MCL was 84·0 months; OS could not be estimated. Toxicities were primarily haematological.

Original languageEnglish (US)
JournalBritish Journal of Haematology
DOIs
StatePublished - Jan 1 2019

Fingerprint

Cladribine
Mantle-Cell Lymphoma
B-Cell Lymphoma
Non-Hodgkin's Lymphoma
Disease-Free Survival
Confidence Intervals
Survival
DNA Methylation
Acetylation
Histones
Lymphoma
vorinostat
Rituximab

Keywords

  • epigenetic
  • mantle cell lymphoma
  • non-Hodgkin lymphoma
  • overall response

ASJC Scopus subject areas

  • Hematology

Cite this

Phase 1–2 study of vorinostat (SAHA), cladribine and rituximab (SCR) in relapsed B-cell non-Hodgkin lymphoma and previously untreated mantle cell lymphoma. / Spurgeon, Stephen; Sharma, Kamal; Claxton, David F.; Ehmann, Christopher; Pu, Jeffrey; Shimko, Sara; Stewart, August; Subbiah, Nan; Palmbach, Gundula; LeBlanc, Francis; Latour, Emile; Chen, Yiyi; Mori, Motomi (Tomi); Hasanali, Zainul; Epner, Elliot M.

In: British Journal of Haematology, 01.01.2019.

Research output: Contribution to journalArticle

Spurgeon, Stephen ; Sharma, Kamal ; Claxton, David F. ; Ehmann, Christopher ; Pu, Jeffrey ; Shimko, Sara ; Stewart, August ; Subbiah, Nan ; Palmbach, Gundula ; LeBlanc, Francis ; Latour, Emile ; Chen, Yiyi ; Mori, Motomi (Tomi) ; Hasanali, Zainul ; Epner, Elliot M. / Phase 1–2 study of vorinostat (SAHA), cladribine and rituximab (SCR) in relapsed B-cell non-Hodgkin lymphoma and previously untreated mantle cell lymphoma. In: British Journal of Haematology. 2019.
@article{3943440cd5fd413b80afac5f795f7a06,
title = "Phase 1–2 study of vorinostat (SAHA), cladribine and rituximab (SCR) in relapsed B-cell non-Hodgkin lymphoma and previously untreated mantle cell lymphoma",
abstract = "Altered DNA methylation and histone acetylation in lymphoma provided the rationale for using vorinostat (SAHA), cladribine and rituximab (SCR) in non-Hodgkin lymphomas (NHL) in this phase 1–2 study (NCT00764517). Treatment included cladribine 5 mg/m2 intravenously (IV) (days 1–5), rituximab 375 mg/m2 IV (weekly 4× for cycle 1 and 1×/month) and vorinostat orally once daily (days 1–14) every 28 days for up to six cycles. Phase 1 included relapsed patients (n = 10) in a standard 3 + 3 dose escalation design (vorinostat: 200, 300 and 400 mg). No dose-limiting toxicities were seen. The phase 2 dose for vorinostat was 400 mg po (days 1–14). The majority of phase 2 patients had mantle cell lymphoma (MCL) (n = 57; 39 previously untreated, 10 relapsed). The primary objective was objective response rate [complete response (CR) + partial response] which was 39{\%} (7/18) in relapsed patients and 97{\%} (38/39) with 80{\%} (31/39) attaining a CR in previously untreated MCL. At a median follow-up of 42 months, median progression-free survival (PFS) and overall survival (OS) for relapsed NHL were 19·5 [95{\%} confidence interval (CI): 2·0–33·0] and 25·0 (95{\%} CI: 12·0–45·0) months respectively. Median PFS for previously untreated MCL was 84·0 months; OS could not be estimated. Toxicities were primarily haematological.",
keywords = "epigenetic, mantle cell lymphoma, non-Hodgkin lymphoma, overall response",
author = "Stephen Spurgeon and Kamal Sharma and Claxton, {David F.} and Christopher Ehmann and Jeffrey Pu and Sara Shimko and August Stewart and Nan Subbiah and Gundula Palmbach and Francis LeBlanc and Emile Latour and Yiyi Chen and Mori, {Motomi (Tomi)} and Zainul Hasanali and Epner, {Elliot M.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1111/bjh.16008",
language = "English (US)",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Phase 1–2 study of vorinostat (SAHA), cladribine and rituximab (SCR) in relapsed B-cell non-Hodgkin lymphoma and previously untreated mantle cell lymphoma

AU - Spurgeon, Stephen

AU - Sharma, Kamal

AU - Claxton, David F.

AU - Ehmann, Christopher

AU - Pu, Jeffrey

AU - Shimko, Sara

AU - Stewart, August

AU - Subbiah, Nan

AU - Palmbach, Gundula

AU - LeBlanc, Francis

AU - Latour, Emile

AU - Chen, Yiyi

AU - Mori, Motomi (Tomi)

AU - Hasanali, Zainul

AU - Epner, Elliot M.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Altered DNA methylation and histone acetylation in lymphoma provided the rationale for using vorinostat (SAHA), cladribine and rituximab (SCR) in non-Hodgkin lymphomas (NHL) in this phase 1–2 study (NCT00764517). Treatment included cladribine 5 mg/m2 intravenously (IV) (days 1–5), rituximab 375 mg/m2 IV (weekly 4× for cycle 1 and 1×/month) and vorinostat orally once daily (days 1–14) every 28 days for up to six cycles. Phase 1 included relapsed patients (n = 10) in a standard 3 + 3 dose escalation design (vorinostat: 200, 300 and 400 mg). No dose-limiting toxicities were seen. The phase 2 dose for vorinostat was 400 mg po (days 1–14). The majority of phase 2 patients had mantle cell lymphoma (MCL) (n = 57; 39 previously untreated, 10 relapsed). The primary objective was objective response rate [complete response (CR) + partial response] which was 39% (7/18) in relapsed patients and 97% (38/39) with 80% (31/39) attaining a CR in previously untreated MCL. At a median follow-up of 42 months, median progression-free survival (PFS) and overall survival (OS) for relapsed NHL were 19·5 [95% confidence interval (CI): 2·0–33·0] and 25·0 (95% CI: 12·0–45·0) months respectively. Median PFS for previously untreated MCL was 84·0 months; OS could not be estimated. Toxicities were primarily haematological.

AB - Altered DNA methylation and histone acetylation in lymphoma provided the rationale for using vorinostat (SAHA), cladribine and rituximab (SCR) in non-Hodgkin lymphomas (NHL) in this phase 1–2 study (NCT00764517). Treatment included cladribine 5 mg/m2 intravenously (IV) (days 1–5), rituximab 375 mg/m2 IV (weekly 4× for cycle 1 and 1×/month) and vorinostat orally once daily (days 1–14) every 28 days for up to six cycles. Phase 1 included relapsed patients (n = 10) in a standard 3 + 3 dose escalation design (vorinostat: 200, 300 and 400 mg). No dose-limiting toxicities were seen. The phase 2 dose for vorinostat was 400 mg po (days 1–14). The majority of phase 2 patients had mantle cell lymphoma (MCL) (n = 57; 39 previously untreated, 10 relapsed). The primary objective was objective response rate [complete response (CR) + partial response] which was 39% (7/18) in relapsed patients and 97% (38/39) with 80% (31/39) attaining a CR in previously untreated MCL. At a median follow-up of 42 months, median progression-free survival (PFS) and overall survival (OS) for relapsed NHL were 19·5 [95% confidence interval (CI): 2·0–33·0] and 25·0 (95% CI: 12·0–45·0) months respectively. Median PFS for previously untreated MCL was 84·0 months; OS could not be estimated. Toxicities were primarily haematological.

KW - epigenetic

KW - mantle cell lymphoma

KW - non-Hodgkin lymphoma

KW - overall response

UR - http://www.scopus.com/inward/record.url?scp=85067669899&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067669899&partnerID=8YFLogxK

U2 - 10.1111/bjh.16008

DO - 10.1111/bjh.16008

M3 - Article

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

ER -